Clinical Trial: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With NK/T-cell Lymphoma

Brief Summary: The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F- FDG PET/CT and predict disease progression during chemotherapy or survival in NK/T-cell lymphoma.

Detailed Summary: In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in NK/T-cell lymphoma. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.
Sponsor: Beijing Cancer Hospital

Current Primary Outcome: Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles [ Time Frame: baseline(diagnosed by pathology and before chemotherapy) and 2 or 4 cycles after starting chemotherapy (each cycle 21days)] ]

Original Primary Outcome: Same as current

Current Secondary Outcome: 3 year progression-free survival [ Time Frame: up to 3 years after initial diagnosis ]

Original Secondary Outcome: Same as current

Information By: Beijing Cancer Hospital

Dates:
Date Received: February 9, 2017
Date Started: March 1, 2017
Date Completion: December 31, 2020
Last Updated: February 9, 2017
Last Verified: February 2017